The Quantellect read.As of Nov 19, 2026, 5 active firms cover Kalaris Therapeutics, Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $14.00 to $25.00, a moderate spread. The average target of $18.67 sits 1283% above the current $1.35. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.57 next quarter toward $-1.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$18.67
+1282.7% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.35 current
Highest Target$25.00
Average Target$18.67
Lowest Target$14.00
Detailed analyst forecasts for KLRS
Showing 1–4 of 4 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate KLRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
KLRS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.57
Range $-0.57 – $-0.47 · 8 analysts · +30% YoY
Next period, 8 analysts expect Kalaris Therapeutics, Inc. to earn $-0.57 a share (range $-0.57 – $-0.47), versus $-0.44 a year earlier. Full-year consensus is $-1.92, growing to $-1.70 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 8 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $11.4M next year.
Top analysts covering Kalaris Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KLRS.
#1
Daniil Gataulin
Chardan Capital · Rank #51
Buy
$19.00+1307.4% to target
Overall win rate
52%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$25.00+1751.9% to target
Overall win rate
43%
+ Follow
#3
Marc Goodman
Leerink Partners · Rank #251
Buy
$20.00+1381.5% to target
Overall win rate
46%
+ Follow
#4
Tara Bancroft
TD Cowen
Buy
No targeton KLRS
Coverage
—
+ Follow
#5
Judah Frommer
Morgan Stanley
Buy
$14.00+937.0% to target
Coverage
—
+ Follow
KLRS stock forecast FAQ
What is KLRS's average 12-month price target?+
The 3 active firms with a live target average $18.67 for Kalaris Therapeutics, Inc. over the next 12 months, ranging from a $25.00 high to a $14.00 low, as of Nov 19, 2026.
Is KLRS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for KLRS?+
The Street-high target is $25.00 (Citizens), and the Street-low is $14.00 (Morgan Stanley). The average of all 3 active-firm targets is $18.67.
How many active Wall Street firms cover KLRS?+
5 active firms have a recognized rating on Kalaris Therapeutics, Inc. as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering KLRS?+
Among analysts who currently cover KLRS, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #51). Their current call is Buy with a $19.00 target.
What is Kalaris Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.57 per share (range $-0.57 – $-0.47) across 8 analysts. Full-year EPS is projected at $-1.92, rising to $-1.70 the following year.
How much revenue is Kalaris Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $11.4M next year.
Have analysts been upgrading or downgrading KLRS lately?+
As of Nov 19, 2026, 5 of 5 active firms rate KLRS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KLRS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.